Research Article

Chlamydia trachomatis and Chlamydia muridarum spectinomycin resistant vectors and a transcriptional fluorescent reporter to monitor conversion from replicative to infectious bacteria

María Eugenia Cortina*, Rachel J. Ende*, R. Clayton Bishop*, Charlie Bayne, Isabelle Derre ID

Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA, United States of America

* These authors contributed equally to this work.

* id8m@virginia.edu

Abstract

Chlamydia trachomatis infections are the leading cause of sexually transmitted infections of bacterial origin. Lower genital tract infections are often asymptomatic, and therefore left untreated, leading to ascending infections that have long-term consequences on female reproductive health. Human pathology can be recapitulated in mice with the mouse adapted strain C. muridarum. Eight years into the post-genetic era, significant advances to expand the Chlamydia genetic toolbox have been made to facilitate the study of this important human pathogen. However, the need for additional tools remains, especially for C. muridarum. Here, we describe a new set of spectinomycin resistant E. coli-Chlamydia shuttle vectors, for C. trachomatis and C. muridarum. These versatile vectors allow for expression and localization studies of Chlamydia effectors, such as Inc proteins, and will be instrumental for mutant complementation studies. In addition, we have exploited the differential expression of specific Chlamydia genes during the developmental cycle to engineer an omcA::gfp fluorescent transcriptional reporter. This novel tool allows for monitoring RB to EB conversion at the bacterial level. Spatiotemporal tracking of GFP expression within individual inclusions revealed that RB to EB conversion initiates in bacteria located at the edge of the inclusion and correlates with the time post initiation of bacterial replication and inclusion size. Comparison between primary and secondary inclusions potentially suggests that the environment in which the inclusions develop influences the timing of conversion. Altogether, the Chlamydia genetic tools described here will benefit the field, as we continue to investigate the molecular mechanisms underlying Chlamydia-host interaction and pathogenesis.
Introduction

*Chlamydia* spp. are Gram-negative obligate intracellular bacterial pathogens that infect a wide range of hosts and are responsible for various diseases. *Chlamydia trachomatis* is the leading cause of sexually transmitted infections of bacterial origin and the most common cause of non-congenital blindness due to trachoma [1]. Infection with *C. pneumoniae* leads to community-acquired pneumonia [2]. *C. felis*, *C. caviae*, and *C. suis* are among *Chlamydia* species that infect animals [3]. Of interest to this study, the mouse-adapted strain *C. muridarum* is commonly used to model human female genital tract infections, because intravaginal *C. muridarum* infection in mice recapitulates the upper genital tract pathology observed with *C. trachomatis* infection in women [4].

*Chlamydia* primarily infects the epithelium of the targeted tissue and replicates within a cytosolic membrane bound compartment, called the inclusion. In the lumen of the inclusion, *Chlamydia* undergoes a bi-phasic developmental cycle that is shared by all species and lasts 2–3 days. This cycle is characterized by alternation between two very distinct morphological and functional forms of the bacterium: a small, electron-dense, infectious elementary body (EB) and a larger, more electron-lucent, replicative reticulate body (RB) [5, 6]. The infection starts with the attachment and internalization of EBs, followed by EB conversion into RB. RBs replicate to high number and, beginning mid-cycle, start their asynchronous conversion back to infectious EBs [7]. At the end of the cycle, inclusions contain a large number of EBs that are released by successive lysis of the inclusion and host plasma membranes or by extrusion [8].

A prolific developmental cycle relies on the maturation of the inclusion into an environment conducive to *Chlamydia* replication. This process depends on the translocation of *Chlamydia* Type III effector proteins [9], some of which, the Inc proteins, are inserted into the inclusion membrane [10–12]. *Chlamydia* species encode 50 to 100 Inc proteins, all of which are characterized by one or more bi-lobed transmembrane domain and cytosolic tails [13]. The inclusion localization and topology of the Inc proteins makes them ideally positioned to mediate inclusion-host cell interactions.

The lack of genetic tools to manipulate *Chlamydia* has significantly hindered our ability to study the *Chlamydia* developmental cycle and characterize the role of *Chlamydia* virulence factors, including Inc proteins. A major breakthrough came from the development of a transformation method for *C. trachomatis* [14] and *E. coli-C. trachomatis* shuttle vectors allowing for fluorescent proteins and tagged-effector expression under constitutive or inducible promoters [14–20], as well as vectors for insertional targeted mutagenesis [21] or allelic replacement [22, 23]. These new genetic tools have been instrumental for live imaging of the *C. trachomatis* inclusion and to get a better understanding of the function of some of *C. trachomatis* Inc proteins [17, 20, 24–33].

In spite of these tremendous advances in the field, the *Chlamydia* genetic toolbox still has some limitations. Most of the shuttle vectors described for *C. trachomatis*, as well as *C. muridarum*, confer resistance to ampicillin, complicating complementation studies of ampicillin resistant mutant strains. Another limitation in the field is that genetic tools for *Chlamydia* species other than *C. trachomatis* are significantly underdeveloped. Due to species barrier specificity for replication, *C. trachomatis*-derived shuttle vectors cannot be maintained in other *Chlamydia* species [34, 35]. Species-specific vectors are therefore needed. Recently, Shima et al. reported the successful transformation and maintenance of a shuttle vector in *C. pneumoniae* [36]. Interestingly, this *C. pneumoniae*-derived vector also replicated in *C. felis*, suggesting that species barrier could be overcome in some instances. Multiple *C. muridarum* vectors have been described and successfully maintained in *C. muridarum*. These vectors were used to study the role of *C. muridarum* proteins encoded by the plasmid or for bioluminescence imaging of ascending infection in whole animals, using a luciferase reporter [34, 35, 37–39]. However,
expression of transgenes has been limited to GFP or luciferase, and plasmid-based expression of effector proteins, such as Inc proteins, has never been performed in *C. muridarum*.

With the advance in *Chlamydia* genetics also comes the opportunity to create tools to monitor RB to EB conversion. Changes in the transcriptional profile of the bacteria as they progress through the developmental cycle have previously been reported [40, 41]. Some genes are expressed early and throughout, while others are expressed mid- to late-cycle as RBs begin to convert to EBs. The *omcAB* operon falls in the latter category. Transcription from this promoter is not initiated until mid-cycle and leads to the production of two cysteine-rich outer membrane proteins that are specific to EBs [40, 42–46]. Such temporal regulation of *Chlamydia* gene transcription offers the possibility to engineer a fluorescent transcriptional reporter indicative of RB to EB conversion at the bacterial level. This reporter would combine, in a single fluorescence assay, the power of methods that currently must be used in combination to accurately monitor the progression of the *Chlamydia* developmental cycle (i.e. inclusion size by immunofluorescence microscopy, bacterial morphology by electron microscopy and production of infectious progeny by Inclusion Forming Units (IFUs) assay). In addition, such a reporter would allow tracking of RB to EB conversion and could validate some of the models that have been proposed to control this process [7, 47].

Here, we describe a new set of spectinomycin resistant *E. coli-Chlamydia* shuttle vectors, for *C. trachomatis* and *C. muridarum*. These versatile vectors allow for expression and localization studies of *Chlamydia* effectors, such as Inc proteins, and will be instrumental for mutant complementation studies as the field further investigates the molecular mechanisms underlying *Chlamydia*-host interaction and pathogenesis. In addition, we have exploited the differential expression of specific *Chlamydia* genes during the developmental cycle to engineer an *omcA::gfp* fluorescent transcriptional reporter. This novel tool allows for monitoring RB to EB conversion at the bacterial level and will be a definite asset to monitor *Chlamydia* developmental growth defects, including in high-throughput assays. Moreover, spatiotemporal tracking of inclusions revealed that RB to EB conversion initiates in bacteria located at the edge of the inclusion and correlates with time post initiation of bacterial replication and inclusion size. In addition, comparison between primary and secondary inclusions potentially suggests that the environment in which the inclusions develop influences the timing of conversion.

### Material and methods

#### Ethics statement

All genetic manipulations and containment work were approved by the UVA Biosafety Committee and are in compliance with the section III-D-1-a of the National Institutes of Health guidelines for research involving recombinant DNA molecules.

#### Cell lines and bacterial strains

HeLa cells were obtained from ATCC (CCL-2) and cultured at 37°C with 5% CO₂ in DMEM high glucose (Invitrogen) supplemented with 10% heat inactivated FBS (Invitrogen). *C. trachomatis Lymphogranuloma venereum, Type II* were obtained from ATCC (L2/434/Bu VR-902B). *C. muridarum* was obtained from Michael Starnbach (Harvard Medical School, Boston, MA). *Chlamydia* propagation and infection were performed as previously described [48].

#### Plasmid construction

Restriction enzymes and T4 DNA ligase were obtained from New England Biolabs (Ipswich, MA). PCR was performed using Herculase DNA polymerase (Stratagene). PCR primers were
obtained from Integrated DNA Technologies and are listed in S1 Table. All inserts were sequenced using Genscript. Plasmid maps were generated using Serial Cloner (http://serialbasics.free.fr/Serial_Cloner.html).

Construction of p2TK2spec. A spectinomycin resistance cassette (Spec) was assembled by overlap PCR using MCSIncDPromFw and aadA-TermOrigRv primers and the following templates: the incDEFG operon promoter, amplified from p2TK2-SW2 IncDProm-mCherrry-IncDTerm [15] with IncDPromNot5 and IncDPromaad3 primers, the aadA open reading frame (ORF), amplified from pDFTT3aadA incA plasmid [49] with IncDPromaad5 and aadTerm3 primers and a terminator [50], amplified with aadTerm5 and TermNot3 primers. In parallel, a DNA fragment corresponding to the E. coli origin of replication and the multiple cloning sites (Ori-MCS) was amplified from the p2TK2Amp vector [15] with aadA-TermOrigFw and MCSIncDPromRv primers. p2TK2spec was constructed by overlap PCR of Ori-MCS and (Spec) with MCSIncDPromFw and MCSIncDPromRv primers.

Construction of p2TK2spec-SW2. pSW2 was obtained by BamHI digest of p2TK2-SW2 mCh(Gro) Tet-IncV-3F plasmid [29] and gel purification of the 7kb band corresponding to pSW2. To construct p2TKspec-SW2, BamHI digested pSW2 was cloned into the BamHI site of p2TK2spec.

Construction of p2TK2spec-SW2 mCh(GroL2). The DNA fragment corresponding to the mCherry ORF, flanked by the groESL operon promoter and terminator was obtained by AgeI digest of p2TK2-SW2 mCh(Gro) Tet-IncV-3F plasmid [29], gel purified and cloned into the AgeI site of p2TK2spec-SW2.

Construction of p2TK2spec-SW2 mCh(GroL2) MCS-3xFLAG. A DNA fragment corresponding to the 3xFLAG and the incDEFG operon terminator was amplified by PCR from p2TK2-SW2 mCh(Gro) Tet-IncV-3F plasmid [29] using primers NotI3XFLAGFw and IncDTermRv and cloned into the NotI/SalI sites of p2TK2spec-SW2 mCh(GroL2) MCS-3xFLAG.

Construction of p2TK2spec-SW2 mCh(GroL2) Tet-IncV-3xFLAG. A DNA fragment corresponding to the tet repressor (TetR), tetA promoter (tetAP) and incV ORF was amplified by PCR from p2TK2-SW2 mCh(Gro) Tet-IncV-3F plasmid [29] using primers TetR-STOP5Kpn and IncVNotIRv and cloned into the KpnI/NotI sites of p2TK2spec-SW2 mCh(GroL2) MCS-3xFLAG.

Construction of p2TK2spec-SW2 mCh(GroL2) Tet-KpnI-IncV-NotI-3xFLAG. A DNA fragment corresponding to the tet repressor and the tetA promoter was amplified by PCR from p2TK2-SW2 mCh(Gro) Tet-IncV-3F plasmid [29] using primers AgeITetRStopFw and TetAPKpnIRv. The incV gene was amplified by PCR from the same template with the KpnIIncVFw and IncVNotIRv primers. These PCR products were sequentially cloned into the AgeI/KpnI and KpnI/NotI sites, respectively, of p2TK2spec-SW2 mCh(GroL2) MCS-3xFLAG.

Construction of p2TK2spec-Nigg. The cloning strategy was inspired by and used plasmids generated by Wang et al. and Skilton et al. [35, 39]. The 7kb BamHI fragment of pSW2NiggCDS2, corresponding to SW2 (CDS3-8 and CDS1) but in which the SW2 CDS2 ORF has been substituted for the Nigg CDS2 ORF [35], was cloned into the BamHI restriction site of p2TK2spec, leading to p2TK2spec-SW2NiggCDS2. Then, a ~6.3kb SpeI/MluI fragment from pGFP::Nigg, corresponding to a portion of CDS2 and CDS3-8 from Nigg [39], was cloned into the ~3kb SpeI/MluI fragment from p2TK2spec-SW2NiggCDS2, corresponding to p2TK2spec, a portion of Nigg CDS2 and SW2 CDS1. The resulting ligation led to p2TK2spec-Nigg. Please note that as for pGFP::Nigg [39], our E. coli- C. muridarum shuttle vector encode all Nigg CDS, except for CDS1 which is from the C. trachomatis SW2 strain.

Construction of p2TK2spec-Nigg mCh(GroL2). The DNA fragment corresponding to the mCherry ORF, flanked by the groESL operon promoter and terminator was obtained by AgeI digest of p2TK2spec-SW2 mCh(GroL2) and gel purification of the corresponding ~1kb
fragment (mCh(Gro\(_{1,2}\)). To construct p2TK2\(_{\text{Spec-Nigg}}\) mCh(Gro\(_{1,2}\)), AgeI digested mCh (Gro\(_{1,2}\)) was cloned into the AgeI restriction site of p2TK2\(_{\text{Spec-Nigg}}\).

**Construction of p2TK2\(_{\text{Spec-Nigg}}\) mCh(Gro\(_{1,2}\)) TetTC0273-3xFLAG.** A DNA fragment corresponding to the TetR-tetA\(_P\) regulatory element was amplified by PCR from p2TK2\(_{\text{Spec-SW2}}\) mCh(Gro\(_{1,2}\)) Tet-IncV-3xFLAG using primers TetRSTOP5Kpn and TetTC02733. A DNA fragment corresponding to the tc0273 ORF was amplified from C. muridarum genomic DNA by PCR using primers TetTC02735 and 0273FLAG3. A DNA fragment corresponding to 3xFLAG incDEFG terminator was amplified by PCR from p2TK2\(_{\text{Spec-SW2}}\) mCh(Gro\(_{1,2}\)) Tet-IncV-3xFLAG using primers 0273FLAG5 and IncDTerm3NotI. A DNA fragment corresponding to TetR-tetA\(_P\) TC0273 3xFLAG incDEFG terminator was amplified by overlapping PCR and cloned into the KpnI/NotI sites of p2TK2\(_{\text{Spec-Nigg}}\) mCh(Gro\(_{1,2}\)).

**Construction of p2TK2-SW2 mCh(Gro\(_{1,2}\)) GFP(Omc\(_A\))L2.** A DNA fragment corresponding to the intergenic region upstream of the omcAB operon was amplified by PCR from C. trachomatis L2 genomic DNA using primers OmcAProm5Kpn and OmcARSGFP3. A DNA fragment corresponding to GFP and incDEFG terminator was amplified from p2TK2-SW2 IncDProm-RSGFP-IncDTerm [15] using primers OmcARSGF5 and IncDTerm3NotI. A DNA fragment corresponding to omcA promoter-GFP-incDEFG terminator was amplified by overlapping PCR and cloned into the KpnI/NotI sites of p2TK2-SW2 mCh(Gro\(_{1,2}\)) [15]. Please note that this plasmid confers resistance to ampicillin.

**Construction of p2TK2\(_{\text{Spec-Nigg}}\) mCh(Gro\(_{1,2}\)) GFP(Omc\(_A\))Cm.** A DNA fragment corresponding to the intergenic region upstream of the omcAB operon was amplified by PCR from C. muridarum genomic DNA using primers CmOmcAProm3KpnI and CmOmcAPromRSGFP3. A DNA fragment corresponding to GFP and the C. trachomatis incDEFG terminator was amplified from p2TK2-SW2 mCh(Gro\(_{1,2}\)) GFP(Omc\(_A\))L2 using primers CmOmcApromRSGF5 and IncDTerm3NotI. A DNA fragment corresponding to omcA\(_{\text{Cm}}\) promoter-GFP-incDEFG terminator was amplified by overlapping PCR and cloned into the KpnI/NotI restriction sites of p2TK2\(_{\text{Spec-Nigg}}\) mCh(Gro\(_{1,2}\)).

**C. trachomatis and C. muridarum transformation**

Our calcium-based transformation protocol was adapted from Wang et al. [14] and modified from Agaisse et al. [15] as follows. For one transformation the reaction was set by combining 500ng of plasmid DNA (extracted from the E. coli GM2163 (dam\(^{-}\)dcm\(^{-}\)) strain), C. trachomatis or C. muridarum (empirically determined so that 100% of the cells were infected), 6.7μl of 5X CaCl\(_2\) Buffer (50mM Tris, 250mM CaCl\(_2\) pH 7.4), and water to a final volume of 33.5μl, added in that order and incubated for 30min at room temperature. Mixing the reaction by pipetting up and down every 5min can be performed but is not necessary. At the end of the 30min, 2ml of media (DMEM high glucose supplemented with 10% FBS) was added to the transformation reaction and transferred to one well of a 6 well plate containing a confluent monolayer of HeLa cells (5x10\(^5\) cells plated the day before). The plate was centrifuged for 10–15 min at 1,200 rpm and incubated for 36-48h at 37˚C in the presence of 5% CO\(_2\). At 12-18h post-infection (p.i.), the media was removed and 2ml of fresh media supplemented with 500μg/ml spectinomycin (Fisher BioRegent) and 1μg/ml of cycloheximide (Sigma) was added. The first passage was performed at 36-48h p.i. (36h p.i. was favored for C. muridarum). The media was removed and the infected cells were lysed by addition of 0.5ml of water/well, scraped, collected and spun for 5min at 1,200rpm. The supernatant was diluted in 2ml of media containing 500μg/ml spectinomycin and 1μg/ml cycloheximide and added to a fresh cell monolayer (seeded the day before) and incubated for 48 h at 37˚C in the presence of 5% CO\(_2\). Passages were performed until enough infectious particles were recovered to generate a
frozen stock and proceed to plaque purification. For both *C. trachomatis* and *C. muridarum*, transformants were routinely observed at the second passage and occasionally observed after the first passage.

**Immunoblotting**

Protein samples were separated by SDS-PAGE and transferred to nitrocellulose membranes. The membranes were blocked for 1h at room temperature in 1xPBS containing 0.05% Tween and 5% fat-free milk. Primary and HRP-conjugated secondary antibodies were diluted in 1xPBS containing 0.05% Tween and 5% fat-free milk and respectively incubated overnight at 4°C and 1h at room temperature. Proteins were detected using the Amersham ECL immunoblotting detection reagent as per manufacturer recommendation and a Bio-Rad ChemiDoc imaging system.

**Immunofluorescence and microscopy**

At the indicated times, HeLa cells seeded onto glass coverslips were fixed for 30 min in PBS containing 4% paraformaldehyde. Immunostainings were performed at room temperature. Antibodies were diluted in PBS containing 0.1% Triton X-100. Samples were washed with PBS and examined under an epifluorescence or spinning disc confocal microscope. Images were processed using the Imaris software (Bitplane, Belfast, United Kingdom).

**Antibodies**

The following primary antibodies were used: mouse monoclonal anti-FLAG (1:1,000 (IF), 1:10,000 (WB), Sigma), rabbit polyclonal anti-GFP (1:2,000, Molecular Probes), rabbit polyclonal anti-mCherry (1:2,000, BioVision), and rabbit polyclonal anti-actin (1:10,000, Sigma). The rabbit polyclonal anti-OmcA was generated against a synthetic OmcA peptide (CGGDTHQDAEHGPQARE) by Alpha Diagnostic International and used at 1:10,000. The following secondary antibodies were used: peroxidase-conjugated goat anti-rabbit IgG (1:10,000, Jackson ImmunoResearch), peroxidase-conjugat ed goat anti-mouse IgG (1:10,000, Jackson ImmunoResearch), and goat anti-mouse AlexaFluor 488 (1:500, Invitrogen).

**Time-lapse video microscopy**

HeLa cells were seeded in 8 well Lab-Tek II Chambered Coverglass dishes (MatTek, Ashland, MA) and infected with the indicated fluorescent *C. trachomatis* or *C. muridarum* strain at a multiplicity of infection of 0.2. At 8h p.i. and for the next 70h, images were captured every 20min on a Leica DMi8 confocal microscope equipped with the Andor iXon ULTRA 888BV EMCCD camera, CSU-W1 confocal scanner unit, and a humidified live cell environmental chamber set at 37°C and 5% CO₂. The Imaris imaging software (Bitplane, Belfast, United Kingdom) was used to analyze and process the data. Videos were converted to mp4 format using the HandBrake compression platform.

**Spatiotemporal analysis of RB to EB transition in *C. trachomatis***

Confocal time lapse videos were analyzed using the Imaris imaging software (Bitplane, Belfast, United Kingdom) by tracking individual inclusions in space and time. Quantification was performed on three independent confocal time lapse imaging experiments. A total of 46 primary inclusions and 29 secondary inclusions were analyzed. Secondary inclusions were distinguished from primary inclusions based on time of inclusion appearance and the timing of
primary inclusion lysis. The graphs were generated using GraphPad Prism. A Student’s t test was performed and statistical significance was set to \( P < 0.0001 \).

**Quantification of time to GFP Expression:** The frame in which an inclusion containing 4–6 mCherry-positive RBs was clearly identifiable and the frame in which GFP expression is first visible within that same inclusion were identified. The 20-minute frame rate was then used to calculate the time elapsed between 4–6 mCherry-positive RBs and the start of GFP expression.

**Quantification of inclusion volume at time of GFP expression:** For each inclusion, at the time of first GFP expression, a single three-dimensional object corresponding to the raw mCherry signal of the bacteria was generated. The volume of the inclusion was calculated as the sum of the pixels within the 3D object.

**Tracking of the spatial distribution of the GFP signal over time:** Individual inclusions were tracked for 120 min after GFP expression was first visible. At each 20 min time mark, the spatial distribution of the GFP signal within individual inclusions was determined by analyzing individual Z stacks of covering the entire inclusion and recording if the signal was at the edge of the inclusion (edge), within the inclusion lumen (internal), or at both the edge and lumen (edge and internal). The mCherry signal of the bacteria was used to determine the boundaries of the inclusion.

**Results**

**A new set of spectinomycin resistant cloning vectors for *Chlamydia trachomatis***

Following the development of a transformation system for *Chlamydia* [14], we described a series of p2TK2_Amp-SW2 *E. coli-C. trachomatis* shuttle cloning vectors [15, 17]. These plasmids encode an ampicillin resistance cassette. Based on a report by Lowden et al. that spectinomycin could also be used to select *C. trachomatis* transformants [49], we generated a new series of p2TK2-SW plasmids. The simplest vector of this series is referred to as p2TK2_Spec-SW2. It is very similar to p2TK2_Amp-SW2 [15], except that it encodes the aminoglycoside 30 adenyltransferase gene (*aadA*), which confers resistance to spectinomycin. The *incDEFG* promoter, which is expressed throughout the developmental cycle [40], was chosen to drive the expression of the *aadA* gene to ensure the constitutive expression of the antibiotic resistance. The presence of a multiple cloning site (MCS) facilitates the cloning of any transgene of interest.

p2TK2_Spec-SW2 was further improved by the addition of a constitutively expressed mCherry fluorescent reporter driven by the *groESL* promoter, as previously described for our p2TK2_Amp-SW2 derivatives [17]. The map and the sequence of the corresponding vector, which is referred to as p2TK2_Spec-SW2 mCh(Gro12), are respectively shown in Fig 1A and S1 Fig. We have also adapted p2TK2_Spec-SW2 mCh(Gro12), to include a 3xFLAG tag downstream from the NotI restriction site and upstream from the *incDEFG* terminator, to allow for convenient cloning and expression of translational fusion between *C. trachomatis* ORFs of interest and the 3xFLAG tag. The map and sequence of the corresponding vector, p2TK2_Spec-SW2 mCh(Gro12) MCS-3xFLAG, are presented in Fig 1B and S2 Fig, respectively.

We have also engineered the p2TK2_Spec-SW2 mCh(Gro12) vector to include the TetR repressor and the *tetA* promoter (*tetA^P*) to express *C. trachomatis* ORFs from the anhydrotestracycline (*aTc*)-inducible promoter. A first vector, p2TK2_Spec-SW2 mCh(Gro12) Tet-IncV-3xFLAG was constructed by cloning a DNA fragment generated by overlapping PCR and comprising of TetR-*tetA^P*-IncV into the KpnI and NotI restriction sites of p2TK2_Spec-SW2 mCh(Gro12) MCS-3xFLAG. The map and sequence of the resulting plasmid are presented in Fig 1C and S3 Fig, respectively. This configuration allows for a seamless junction between
and the start codon of IncV, which has been our preferred arrangement to avoid a potential disruption of aTc regulation [17, 27, 29, 51].

In an attempt to streamline the cloning process and avoid multiple rounds of overlap PCR, a second vector, p2TK2\text{spec}-SW2 mCh(Gro\text{L2}) Tet-IncV-3xFLAG was also generated (Fig 1D and S4 Fig for map and sequence respectively). With this configuration, the KpnI and NotI restriction sites present downstream of the TetR-tet\text{A} promoter and upstream of the 3xFLAG allow for a single step cloning of any gene of interest. The potential downside of this configuration is the introduction of a KpnI restriction site between tet\text{A} and the start codon of the downstream ORF, which could negatively affect the aTc dependent expression (see below).

Altogether, we present a new set of versatile, spectinomycin resistant expression vectors for

C. trachomatis.

Addition of nucleotides between tet\text{A} and the downstream ORF can affect aTc induction

We next tested if introducing a KpnI restriction site between tet\text{A} and the start codon of the downstream ORF would affect aTc induction. For this purpose, we used the T3SS effector
IncV. We generated and introduced in \textit{C. trachomatis} p2TK2\textsubscript{Spec-SW2} mCh(Gro\textsubscript{L2}) Tet-\textit{IncV-3xFLAG} and p2TK2\textsubscript{Spec-SW2} mCh(Gro\textsubscript{L2}) Tet-KpnI-\textit{IncV-3xFLAG}. The transformants were plaque purified and IncV expression was determined by immunoblot or immunofluorescence in the absence or presence of aTc. As previously observed with our Amp\textsubscript{R} vector [29], the Tet-\textit{IncV-3xFLAG} configuration led to the tight repression of IncV expression in the absence of aTc, with no IncV-3xFLAG protein detectable by immunoblot or immunofluorescence (Fig 1E left lane and 1F top panels). Addition of aTc, led to IncV-3xFLAG expression and localization to the inclusion membrane (Fig 1E right lane and 1F bottom panels). Similar levels of IncV-3xFLAG expression were obtained with aTc induction of the Tet-KpnI-\textit{IncV-NotI-3xFLAG} construct (Fig 1G, right lane and 1H bottom panels). However, and although to a lesser extent, the IncV-3xFLAG protein was also expressed in the absence of aTc, as determined both by immunoblot and immunofluorescence (Fig 1G left lane and 1H top panels).

Altogether, these results suggest that introducing a KpnI restriction site between tetA\textsubscript{P} and the start codon of IncV affected the aTc dependent repression of the promoter leading to weak but constitutive expression of the construct in the absence of inducer.

A spectinomycin resistant cloning vectors for \textit{Chlamydia muridarum}

Skilton et al. have recently described, pGFP-Nigg, an \textit{E. coli-}\textit{C. muridarum} shuttle vector encoding CDS2-8 from the \textit{C. muridarum} Nigg plasmid and CDS1 from the \textit{C. trachomatis} SW2 plasmid, an ampicillin resistance cassette, and the green fluorescent protein (GFP) [39]. We have generated a different version of this plasmid, referred to as p2TK2\textsubscript{Spec-Nigg}, which includes a spectinomycin selectable marker (aadA under the \textit{C. trachomatis incDEFG} promoter) and a MCS (see material and methods for details on cloning strategy) (Fig 2A and S5 Fig for map and sequence respectively). In addition, we have introduced the mCherry reporter under the control of the \textit{C. trachomatis groESL} promoter to generate p2TK2\textsubscript{Spec-Nigg} mCh(Gro\textsubscript{L2}) (Fig 2B and S6 Fig for map and sequence respectively). The latter was transformed into \textit{C. muridarum} following the same protocol used for \textit{C. trachomatis} and led to mCherry expressing \textit{C. muridarum} at the second passage (Cm mCherry). mCherry expression was stable after plaque purification of the strain (Fig 2C).

Altogether, these results indicate that spectinomycin can be used as a selectable marker for \textit{C. muridarum} and that \textit{C. trachomatis} promoters (i.e. \textit{incDEFG} and \textit{groESL} operon) and mCherry are expressed in \textit{C. muridarum}.

aTc inducible gene expression in \textit{C. muridarum}

We next tested if the Tet system could be used for inducible gene expression in \textit{C. muridarum}. For this purpose, the tc0273 ORF, which encodes the \textit{C. muridarum} IncV homolog, was cloned as a 3xFLAG translational fusion under the control of the tetA inducible promoter into the KpnI and NotI restriction sites of p2TK2\textsubscript{Spec-Nigg} mCh(Gro\textsubscript{L2}). Based on our results with \textit{C. trachomatis} (Fig 1), we chose the configuration in which the tc0273 ORF is seamlessly attached to tetA\textsubscript{P} to ensure tight repression. The map and sequence of the resulting plasmid are presented in Fig 2D and S7 Fig, respectively. \textit{C. muridarum} transformation resulted in mCherry expressing transformants that were plaque purified. In the absence of aTc, the resulting strain expressed mCherry only, as assayed by immunoblot and immunofluorescence (Fig 2E left lane and 2F top panels). In the presence of aTc, TC0273-3xFLAG expression was induced and detectable by immunoblot (Fig 2E right lane). TC0273-3xFLAG expression was confirmed by immunofluorescence microscopy, which also revealed that, as observed for its \textit{C. trachomatis} homologue, TC0273 localized to the inclusion membrane (Fig 2F bottom panels).
Altogether, these results demonstrated that the Tet system can be used for inducible gene expression in *C. muridarum* and for studying the cellular localization of *C. muridarum* effectors, such as Inc proteins.

**A transcriptional fluorescent reporter to monitor RB to EB transition**

Constitutive expression of a fluorescent reporter such as mCherry is a useful tool to monitor inclusion expansion, however it does not inform if and when the bacteria have undergone RB or EB conversion. For this purpose, we took advantage of the fact that a subset of *C. trachomatis* genes are expressed late in the developmental cycle, as the bacteria transition from RB to EB [40, 41]. One such gene is *omcA*. GFP was cloned under the control of the *C. trachomatis* *omcA* promoter and introduced between the Knpl and NotI restriction sites of p2TK2.

---

https://doi.org/10.1371/journal.pone.0217753.g002
SW2 mCh(Gro12). The resulting plasmid, p2TK2Spc-SW2 mCh(Gro12) GFP(OmcA12) (Fig 3A and S8 Fig for map and sequence, respectively) was transformed into C. trachomatis and the resulting strain, referred to as Ct mCh(Gro12) GFP(OmcA12), was plaque purified. Expression of mCherry or mCherry and GFP did not affect bacterial replication (not shown).

HeLa cells were infected with this strain or with C. trachomatis expressing mCherry only (Ct mCh(Gro12)). At various times from 18h p.i., when the inclusions mostly harbor RBs, to 44h p.i., when C. trachomatis completes its developmental cycle and most of the bacteria have converted to EB, samples were collected and analyzed by immunoblot using antibodies against GFP, OmcA, mCherry and actin (Fig 3C). Quantification of three independent experimental replicates are presented in Fig 3D and 3E. As expected for a constitutively expressed reporter, both strains were positive for mCherry at all time points analyzed (Fig 3C mCherry and 3D and 3E red line). Also as expected, the overall intensity of the mCherry signal increased over time, especially during the first 30h, reflecting RB multiplication. For both strains, a weak OmcA signal was detectable starting at 28h p.i., when asynchronous RB to EB conversion is occurring. The OmcA signal intensified over time as the developmental cycle progressed and more RBs transitioned into EBs (Fig 3C OmcA and 3D and 3E black line). Additionally, GFP was only detected in the Ct mCh(Gro12) GFP(omcA12) strain, and most importantly for the validation of our approach, the expression of GFP mirrored the expression of endogenous OmcA (Fig 3C GFP and 3D and 3E green line).

Altogether these results indicate that, at the population level, GFP expression from the C. trachomatis omcA promoter correlates with the expression of endogenous OmcA and therefore constitute an adequate reporter of the RB to EB conversion during C. trachomatis developmental cycle.

Visualizing C. trachomatis RB to EB transition by time lapse-microscopy

We next performed time-lapse confocal microscopy to visualize the expression of the mCherry and GFP reporters at a single inclusion level. For this purpose, HeLa cells infected with the Ct mCh(Gro12) or Ct mCh(Gro12) GFP(OmcA12) strain were imaged starting 8h p.i. Z stacks were acquired every 20min for 70h to capture several rounds of infections. Selected frames and the corresponding movies are presented in Fig 3F and S1 and S2 Movies, respectively. With the Ct mCh (Gro12) strain, mCherry expression was detected early when the inclusion harbored only a few bacteria (Fig 3F, top panels, Primary inclusions, 16h). Moreover, the bacteria remained fluorescent during the entire duration of the movie, which included the formation of primary and secondary inclusions (Fig 3F, top panels, Secondary inclusions, 56h). The Ct mCh(Gro12) GFP (omcA12) strain presented similar timing of mCherry expression to the Ct mCh(Gro12) strain (Fig 3F, bottom panels, Primary inclusions). In addition, in primary inclusions, a few bacteria started to express GFP at 26h p.i. (Fig 3F, bottom panels, Primary inclusions, 26h). The number of GFP-positive bacteria per inclusion progressively increased over time, until the inclusion was eventually filled with GFP-expressing bacteria (Fig 3F, bottom panels, Primary inclusions). Importantly, the same pattern of mCherry and GFP expression was observed during secondary infections. Early on, secondary inclusions were mCherry-positive only and displayed increasing GFP expression as time progressed (Fig 3F, bottom panels, Secondary inclusions, compare 56h and 60h), further confirming the temporal regulation of the GFP reporter.

Altogether, these results indicate that our fluorescent reporters allow for live imaging of early to late events of C. trachomatis developmental cycle. Moreover, we showed that, in C. trachomatis, the omcA promoter-dependent expression of GFP leads to a temporal expression, which correlates with the late developmental stages of the bacteria, therefore constituting an adequate reporter for monitoring C. trachomatis RB to EB conversion.
Expanding the *Chlamydia* genetic toolbox

**A**

![Diagram of p2TK2-SW2 with mCh(GroL2) and GFP(OmcA2)]

- `p2TK2-SW2`
- `mCh(GroL2)`
- `GFP(OmcA2)`
- `11417bp`

**B**

![Diagram of p2TK2spec-Nigg with mCh(GroL2) and GFP(OmcAcm)]

- `p2TK2spec-Nigg`
- `mCh(GroL2)`
- `GFP(OmcAcm)`
- `11662bp`

**C**

![Images of GFP expression over time]

- `Ct mCh(GroL2)`
- `GFP`
- `OmcA`
- `mCherry`
- `Actin`

**D**

![Graphs showing protein levels over time for GFP, OmcA, and mCherry]

**E**

![Graphs showing protein levels over time for GFP, OmcA, and mCherry]

**F**

**Primary Inclusions**

| 16 hpi | 20 hpi | 21 hpi | 26 hpi | 31 hpi | 41 hpi | 55 hpi | 75 hpi |
|--------|--------|--------|--------|--------|--------|--------|--------|
| ![Image](image1) | ![Image](image2) | ![Image](image3) | ![Image](image4) | ![Image](image5) | ![Image](image6) | ![Image](image7) | ![Image](image8) |

**Secondary Inclusions**

| 56 hpi | 60 hpi |
|--------|--------|
| ![Image](image9) | ![Image](image10) |

**G**

**Primary Inclusions**

| 15 hpi | 16 hpi | 20 hpi | 21 hpi | 25 hpi | 31 hpi | 35 hpi | 41 hpi |
|--------|--------|--------|--------|--------|--------|--------|--------|
| ![Image](image11) | ![Image](image12) | ![Image](image13) | ![Image](image14) | ![Image](image15) | ![Image](image16) | ![Image](image17) | ![Image](image18) |

**Secondary Inclusions**

| 45 hpi | 50 hpi |
|--------|--------|
| ![Image](image19) | ![Image](image20) |
Fig 3. Transcriptional fluorescent reporters to monitor RB to EB transition in *C. trachomatis* and *C. muridarum*. Vector maps of p2TK2-SW2 mCh(Gro12)GFP (OmcA12) (A) and p2TK2-Nigg mCh(Gro12)GFP(OmcACm) (B). The pSW2 and pNigg plasmids are shown in black; the incDEFG promoter in dark blue; the spectinomycin resistance gene (*aadA*) and ampicillin resistance gene (*bla*) in blue; the terminator in light blue; the *E. coli* origin of replication (Ori) in grey; the groESL promoter in dark red; mCherry ORF in red; the groESL terminator in light red; the omcA promoter in dark green; GFP in green; the incDEFG terminator in light green; unique restriction sites in purple. (C-D) Immuno-blot of cell lysates from HeLa cells infected with a strain of *C. trachomatis* transformed with p2TK2spec-SW2 mCh(Gro12) or p2TK2spec-SW2 mCh(Gro12) GFP(OmcA12). Lysates were collected at the indicated time and probed using antibodies against GFP, OmcA, mCherry, and actin. (D-E) Quantification of the signal intensity of the indicated marker from immunoblots as shown in (C). The average signal intensity from three independent experiments is shown. mCherry: red; OmcA: black and GFP: green. (F-G) Selected 3-dimensional merged frames from Video S1 (Top panels, (F)), Video S2 (Bottom panels, (F)), Video S3 (Top panels, (G)) and Video S4 (Bottom panels, (G)) acquired by time-lapse video confocal microscopy of HeLa cells infected with *C. trachomatis* (F) or *C. muridarum* (G) expressing mCherry (red) from the groESL promoter (Top panels) or mCherry (red) and GFP (green) under the control of the *C. trachomatis* groESL and omcA promoter, respectively (Bottom panels). Frames were selected to provide representative examples of primary (left) and secondary (right) inclusions. The time p.i. is indicated above each frame. Scale Bar: 10 μm.

https://doi.org/10.1371/journal.pone.0217753.g003

Visualizing *C. muridarum* developmental cycle, including RB to EB transition, by time lapse-microscopy

We next investigated if the RB to EB transition omcA reporter could be used in *C. muridarum*. For this purpose, GFP was cloned under the control of the *C. muridarum* omcA promoter and introduced between the KpnI and NotI restriction sites of p2TK2spec-Nigg mCh(Gro12). The resulting plasmid, p2TK2spec-Nigg mCh(Gro12) GFP(OmcACm) (Fig 3B and S9 Fig for map and sequence, respectively) was transformed into *C. muridarum* and the derived strain, *Cm* mCh(Gro12) GFP(OmcACm) was plaque purified. HeLa cells infected with *Cm* mCh(Gro12) or *Cm* mCh(Gro12) GFP(OmcACm) were analyzed by time-lapse confocal microscopy under the same conditions described above for *C. trachomatis*. Selected frames and the corresponding movies are presented in Fig 3G and S3 and S4 Movies, respectively. Live imaging of the *Cm* mCh(Gro12) strain revealed that the mCherry reporter was expressed early and throughout the duration of the movie which included secondary infections (Fig 3G Top panels). In addition, comparison of the kinetics of the developmental cycle of the mCherry expressing *C. trachomatis* and *C. muridarum* strains, indicated that *C. muridarum* developmental cycle appeared to progress faster than *C. trachomatis* developmental cycle (Compare time points of the selected frames in Fig 3F and 3G). Live imaging of the *Cm* mCh(Gro12) GFP(OmcACm) strain revealed that, early on, inclusions were expressing mCherry only, but progressive and increasing appearance of the GFP signal occurred as the developmental cycle progressed (Fig 3G Bottom panels, Primary inclusions). Moreover, nascent secondary inclusions were at first mCherry-positive but GFP-negative (Fig 3G bottom panels, Secondary inclusions, compare 45h and 50h).

Altogether, these results indicated that our mCherry reporter allows for live imaging of early and late events of *C. muridarum* developmental cycle. They also revealed that in our experimental set up *C. muridarum* appeared to go through one round of infection at a faster pace than *C. trachomatis*. Moreover, our data indicated that GFP expression from the *C. muridarum* omcA promoter was temporally regulated and coincided with late stages of the developmental cycle, supporting the use of this reporter for monitoring RB to EB conversion.

Spatiotemporal analysis of RB to EB transition in *C. trachomatis*

To gain insight into the spatiotemporal dynamics of the RB to EB transition, we analyzed when and where the GFP signal was first observed. Time-lapse confocal microscopy was performed on HeLa cells infected with the *Cm* mCh(Gro12) GFP(OmcACm) strain, as described in Fig 3, and individual inclusions were tracked over time. We first quantified the time required for inclusions containing 4 to 6 mCherry-positive bacteria, a stage at which we could confidently identify inclusions, to display the first GFP-positive bacteria (Fig 4A). The fastest and slowest primary inclusions displayed GFP-positive bacteria after 240min and 440min,
respectively. Overall, the average time for the initiation of RB to EB conversion in primary inclusion was 365 min +/- 53 min, once the inclusion contains 4–6 bacteria. This number was significantly reduced in secondary inclusions (268 min +/- 64 min). We also determined that, when the first GFP-positive bacteria were observed, the average volume of the inclusions was 423 μm³ +/- 116 μm³ and 139 μm³ +/- 45 μm³ in primary and secondary inclusions, respectively (Fig 4B).

We next determined if the GFP signal was occurring randomly or at a specific location within the inclusion. For this purpose, primary inclusions were monitored until GFP expression was first detected and the spatial distribution of the GFP signal was tracked and recorded over time. Three categories of inclusions were observed. The GFP signal was at the edge only, at the edge and internally, or internally only (Fig 4C, light green, dark green and orange respectively). In all cases, at the time of conversion, the GFP signal was restricted to one to three bacteria. Tracking of multiple primary inclusions revealed that for 85% of the inclusions, an example of which is provided in Fig 4E, the GFP signal appeared first in one to three bacteria localized at the edge of the inclusion only (Fig 4C, top panel, light green and 4D, Class I, light green). As time progressed, the GFP signal was observed in bacteria localizing at the edge of the inclusion but also in the center of the inclusion (Fig 4C, middle panel, dark green and 4D, Class I, dark green). The time to transition from inclusions containing GFP-positive bacteria at the edge only, to inclusions with GFP-positive bacteria at the edge and internally, ranged from 20 min to 120 min (Fig 4D, Class I). Two inclusions, annotated with an asterisk, required longer (240 min and 160 min). For about 6% of the primary inclusions, the GFP signal was observed at the edge and internally at all time points analyzed (Fig 4C, middle panel, dark green and 4D, Class II, dark green). Because frames were acquired every 20 min, it is possible that we were not able to capture these inclusions with GFP-positive bacterium at the edge only, despite its occurrence. If so, it would suggest that transition from edge only to edge and internal could occur in less that 20 min. Finally, 9% of the primary inclusions displayed the GFP signal internally at first and at the edge and internally later on (Fig 4C, bottom panel, orange and 4D, Class III). It is also possible that the initial GFP expressing bacteria at the edge of the inclusion was missed because of the timing of the acquisition. Secondary inclusions followed the same trend (not shown).

Altogether our spatiotemporal analysis of RB to EB conversion suggests that this process starts at a specific time (365 min +/- 53 min and 268 min +/- 64 min in primary and secondary inclusions, respectively), after the bacteria have undergone 2–3 rounds of replication, and correlates with a specific size of the inclusion (423 μm³ +/- 116 μm³ and 139 μm³ +/- 45 μm³ in primary and secondary inclusions, respectively). In addition, we provide evidence that the first bacteria to convert localize at the edge of the inclusion and that within 20-120 min converting/converted bacteria are observed at the edge and in the lumen of the inclusion.

Discussion

Spectinomycin resistant vectors for Chlamydia

Beta-lactams, such as ampicillin or penicillin, were the first antibiotics used for the selection of C. trachomatis transformants [14]. Chloramphenicol and spectinomycin selections were described later on [21, 49]. However, most of the C. trachomatis vectors available so far display the beta-lactamase gene and therefore cannot be used for the complementation of TargetTron or FRAEM mutants in which the beta-lactamase gene either interrupts or replaces the targeted gene [22, 52]. To circumvent this problem and complement a ct383::bla mutant, Weber et al. inserted the adaA gene under the control of the incD promoter in their pBOMB4-Tet-CT383 vector, leading to a vector that conferred resistance to spectinomycin, in addition to ampicillin
Our p2TK2-SW2 derivatives offer the advantage of conferring resistance to either ampicillin (p2TK2\textsuperscript{Amp}-SW2) or spectinomycin (p2TK2\textsuperscript{Spec}-SW2). Moreover, since their MCS are compatible, transgenes can easily be transferred from one vector to another.

**Cloning downstream of the \textit{tet}^4 \textsuperscript{A} promoter**

We have cloned the \textit{C. trachomatis} \textit{incV} ORF downstream of the \textit{tet}^4 \textsuperscript{A} promoter, either seamlessly, or by introducing a KpnI restriction site between the promoter and the start codon. Seamless junction led to a tight aTc regulation with the construct being off or on in the absence or presence of aTc, respectively. In addition, when expressed, IncV localized to the inclusion membrane. This is in contrast with the construct that included a KpnI site. This configuration led to leaky expression of IncV in the absence of inducer. In addition, a great proportion of the IncV molecules appeared to be trapped inside the bacteria. The only difference between the 2 constructs is the presence of the KpnI restriction, which would suggest that the addition of the corresponding 6 nucleotides is responsible for affecting tight repression, but also translocation. Potential reasons for the latter are unclear to us. Wickstrum et al. included an AgeI site.
between the tetA promoter and start codon of GFP without affecting regulation [16]. Similarly, Bauler et al. used a NotI site [18]. At this point we cannot conclude if our results are specific to IncV and/or KpnI; regardless, they indicate that caution should be taken when designing strategies to clone effectors downstream of the tetA promoter.

A versatile vector for Chlamydia muridarum

Since the development of genetic tools to study Chlamydia, there has been a bias towards C. trachomatis. Tools for C. muridarum, the mouse adapted strain commonly used to model human genital tract ascending infections in mice, are still limited. Most of the vectors described so far have been used to investigate the role of plasmid encoded ORFs in C. muridarum virulence [34, 35, 37–39]. Here, we present C. muridarum vectors that are as versatile as the one described for C. trachomatis. We have shown that in addition to GFP [39] and luciferase [37], mCherry can be expressed in C. muridarum without affecting its developmental cycle. Our study also reveals that spectinomycin can be used to select for transformants, hereby providing an additional selection marker for C. muridarum. By including a MCS, to facilitate the cloning of any transgene of interest, and an aTc inducible promoter, we have performed a tagged effector localization study. Our results indicate that the Tet inducible system is functional in C. muridarum and confirmed the predicted inclusion localization of TC0273 [11]. Altogether, increasing the versatility of C. muridarum vectors will be instrumental for mutant complementation and subsequent in vivo studies.

We were able to image C. muridarum developmental cycle using a constitutive mCherry reporter or a reporter for RB to EB conversion. Our live imaging analysis indicates that constitutive mCherry expression allows for detection of nascent inclusions containing a few RBs. In addition, we noticed that C. muridarum secondary inclusions are detected earlier than C. trachomatis secondary inclusions and that the developmental cycle progresses almost twice as fast as C. trachomatis developmental cycle, in agreement with a previous report [53].

Advantages of a fluorescent reporter to monitor RB to EB conversion

Inclusion Forming Units (IFUs) assay, where the number of infectious bacteria (i.e. EBs) recovered at a given stage of the developmental cycle is determined by infection of a fresh monolayer of cells with serial dilutions of infected cells lysates, is a standard assay to determine if Chlamydia undergoes a productive developmental cycle. While accurately measuring the amount of EBs, this assay is labor intensive, limited in the number of conditions that can be tested at once, and not easily adaptable to high-throughput screening. Moreover, it does not provide information on potential defects in entry, EB to RB conversion or RB replication.

Electron microscopy (EM) has been instrumental in investigating RB to EB conversion due to the clear morphological difference of the two developmental forms [5–7]. Although EM offers the unambiguous identification of the different Chlamydia forms, it is labor intensive and the number of inclusions that can be analyzed is limited. In addition, 3D EM revealed that the distribution of EB and RB within the inclusion is heterogeneous, therefore introducing a bias when analyzing inclusion content by conventional 2D EM [7].

Chlamydia intracellular development can also be evaluated by using a fluorescence-based assay where the surface area of the inclusions, as determined per immunostaining of the bacteria or using fluorescent strains, is quantified using computer assisted software. This assay allows for the analysis of a large number of inclusions and is amenable to high-throughput formats. However, it does not provide a full picture of the developmental cycle. Some inclusions could be large and yet mostly contain RBs. On the contrary, small inclusions could be filled with EBs, as shown with Brefeldin A treatment [54].
Here, we have designed a fluorescent reporter to monitor RB to EB conversion. Our rationale stemmed from earlier studies that demonstrated temporal expression of specific *Chlamydia* genes throughout the developmental cycle [40, 41]. Of particular interest to our design were genes, like *omcA*, whose transcription initiation corresponded to the time of RB to EB conversion. As anticipated, the timing and asynchronous nature of the expression of the transcriptional *omcA:gfp* reporter closely mimics the expression of endogenous OmcA. In addition, the timing of GFP expression, as a readout for RB to EB conversion, was consistent with results from previous EM studies. For example, in their 3D EM analysis of the developmental cycle, Lee et al. observed the first intermediate bodies at 24h p.i. [7], which is the same time point at which we observed the first GFP-expressing *C. trachomatis*. Moreover, Lee et al. also reported that by 40h p.i., 70% of the bacteria were EBs, which is also in agreement with our *C. trachomatis* imaging results where the inclusions were filled with EBs at that time point.

Altogether, our RB to EB conversion reporter offers an alternative that combines the advantages of the assays listed above, while alleviating some of the limitations. Fluorescence microscopy analysis of cells infected with *Chlamydia* strains encoding the fluorescent RB to EB conversion reporter allows for quantification, in a single assay, of: 1) the size of the inclusion based on the mCherry signal, 2) the proportion of GFP-positive inclusions in which RB have converted to EB, 3) the proportion of RB that have converted to EB in a given inclusion (i.e. GFP-positive bacteria). Moreover, live imaging can be used to measure the timing of these events. These readouts would be applicable to genome wide siRNA or CRISPR screens or screening of small molecules that inhibit *Chlamydia* developmental cycle. The reporter could also be introduced in *Chlamydia* mutants to monitor potential growth defects. Finally, one could also envision that this new tool could be instrumental in visualizing the RB to EB transition *in vivo*.

**Spatiotemporal analysis of RB to EB transition in *C. trachomatis***

By tracking individual inclusions harboring our *C. trachomatis* RB to EB reporter strain, we were able to gather spatiotemporal information of RB to EB conversion. In primary inclusions, the timing of the initiation of RB to EB conversion was fairly homogenous and averaged to 365min +/-53min, after the bacteria had undergone 2–3 rounds of replication. It also correlated with similar inclusion volumes (423μm³ +/-116μm³). In secondary inclusions, although the average time to conversion was also consistent from one inclusion to another, it was significantly faster than in primary inclusions (268min +/-64min) and correlated with smaller inclusions (139μm³ +/-45μm³). In our experimental set up, the environment in which primary and secondary inclusions matured was different. Primary inclusions developed in an undisturbed environment, whereas secondary inclusions developed in the presence of lysed infected cells and high numbers of released EB that continue to infect the monolayer. In addition, it is possible that specific nutrients are being depleted, resulting in some level of starvation of the bacteria in secondary inclusions. Altogether our results indicate that the initiation of RB to EB conversion occurs at a specific time after the RBs start to replicate and once the inclusion has reached a certain size. However, the timing and inclusion size appear to vary depending on the environment, suggesting that external signals may also influence this process.

We were also able to visualize where RB to EB conversion is initiated. Our data indicate that the first one to three bacteria to undergo conversion are localized at the edge of the inclusion. Within 20–120 min of the first conversion event, a different set of GFP-expressing bacteria localized at the edge and some GFP-positive bacteria were present in the lumen of the inclusion. These results could fit a model by which RB to EB transition is initiated in bacteria that are in close proximity to the inclusion membrane and is followed by the subsequent
accumulation of converting/converted bacteria in the center of the inclusion. This model would follow the one proposed by Wilson et al. in which replicating RBs are attached to the inclusion though their type III secretion system and over time detachment of RBs from the inclusion membrane provides the signal for differentiation into EB which accumulate in the lumen of the inclusion [47]. Because our experimental setup does not allow us to determine if converting RBs are physically attached to the inclusion membrane, we cannot confirm at this time if RB detachment is required to initiate conversion or if completion of the conversion requires detachment. It is also unclear if the size of the RBs controls this process [7]. Regardless, our data clearly indicate that the first event of RB to EB conversion occurs in RB localized at the periphery of the inclusion.

**Conclusion**

Altogether, we present here a new set of genetic tools for *C. trachomatis* and *C. muridarum* that will be instrumental as the field continues to harness the power of genetics to study this important pathogen.

**Supporting information**

**S1 Table.** Primers used in this study. (DOCX)

**S1 Fig.** p2TK2Spec-SW2 mCh(Gro\textsubscript{1,2}) sequence. (DOCX)

**S2 Fig.** p2TK2Spec-SW2 mCh(Gro\textsubscript{1,2}) MCS-3xFLAG sequence. (DOCX)

**S3 Fig.** p2TK2Spec-SW2 mCh(Gro\textsubscript{1,2}) Tet-IncV-3xFLAG sequence. (DOCX)

**S4 Fig.** p2TK2Spec-SW2 mCh(Gro\textsubscript{1,2}) Tet-KpnI-IncV-NotI-3xFLAG sequence. (DOCX)

**S5 Fig.** p2TK2Spec-Nigg sequence. (DOCX)

**S6 Fig.** p2TK2Spec-Nigg mCh(Gro\textsubscript{1,2}) sequence. (DOCX)

**S7 Fig.** p2TK2Spec-Nigg mCh(Gro\textsubscript{1,2}) TetTC0273-3xFLAG sequence. (DOCX)

**S8 Fig.** p2TK2-SW2 mCh(Gro\textsubscript{1,2}) GFP(OmcA\textsubscript{1,2}) sequence. (DOCX)

**S9 Fig.** p2TK2Spec-Nigg mCh(Gro\textsubscript{1,2}) GFP(OmcA\textsubscript{Cm}) sequence. (DOCX)

**S1 Movie.** Time-lapse video microscopy of the developmental cycle of mCherry expressing *C. trachomatis*. Video S1 shows the development of primary and secondary inclusions of *C. trachomatis* expressing mCherry under the control of the *C. trachomatis* groESL promoter. Infected HeLa cells were monitored starting 8h p.i. by spinning disc confocal microscopy. A z-stack of 40 images covering 40\textmu m was acquired every 20min over the course of 70h. The mp4 video was generated using Imaris imaging software and the HandBrake compression platform.
The video is played at 10 frames/s. The time (hours:min:seconds) is indicated in the upper right corner. Scale Bar: 20μm.

S2 Movie. Time-lapse video microscopy of the *C. trachomatis* developmental cycle using a transcriptional fluorescent reporter to monitor RB to EB transition. Video S2 shows the development of primary and secondary inclusions and the RB to EB transition that occurs during *C. trachomatis* infection. HeLa cells were infected with a *C. trachomatis* strain that expresses mCherry under the control of the *C. trachomatis groESL* promoter and GFP under the control of the *C. trachomatis omcA* promoter. 8h p.i., infected cells were monitored by spinning disc confocal microscopy. A z-stack of 40 images covering 40μm was acquired every 20min over the course of 70h. The mp4 video was generated using Imaris imaging software and the HandBrake compression platform. The video is played at 10 frames/s. The time (hours:min:seconds) is indicated in the upper right corner. Scale Bar: 20μm.

S3 Movie. Time-lapse video microscopy of the developmental cycle of mCherry expressing *C. muridarum*. Video S3 shows the development of primary and secondary inclusions of *C. muridarum* expressing mCherry under the control of the *C. trachomatis groESL* promoter. Infected HeLa cells were monitored starting 8h p.i. by spinning disc confocal microscopy. A z-stack of 40 images covering 40μm was acquired every 20min over the course of 70h. The mp4 video was generated using Imaris imaging software and the HandBrake compression platform. The video is played at 10 frames/s. The time (hours:min:seconds) is indicated in the upper right corner. Scale Bar: 20μm.

S4 Movie. Time-lapse video microscopy of the *C. muridarum* developmental cycle using a transcriptional fluorescent reporter to monitor RB to EB transition. Video S4 shows the development of primary and secondary inclusions and the RB to EB transition that occurs during *C. muridarum* infection. HeLa cells were infected with a *C. muridarum* strain that expressed mCherry under the control of the *C. trachomatis groESL* promoter and GFP under the control of the *C. muridarum omcA* promoter. 8h p.i., infected cells were monitored by spinning disc confocal microscopy. A z-stack of 40 images covering 40μm was acquired every 20min over the course of 70h. The mp4 video was generated using Imaris imaging software and the HandBrake compression platform. The video is played at 10 frames/s. The time (hours:min:seconds) is indicated in the upper right corner. Scale Bar: 20μm.

Acknowledgments

We thank Hervé Agaisse (UVA) for critical reading of the manuscript. This work was supported by NIH grants AI007046 to RJE and RCB, and AI101441 and AI141841 to I.D.

Author Contributions

Conceptualization: Isabelle Derré.

Funding acquisition: Isabelle Derré.

Investigation: Maria Eugenia Cortina, Rachel J. Ende, R. Clayton Bishop, Charlie Bayne.

Methodology: Isabelle Derré.

Supervision: Isabelle Derré.
Validation: Isabelle Derré.
Visualization: María Eugenia Cortina, Rachel J. Ende, R. Clayton Bishop, Charlie Bayne, Isabelle Derré.
Writing – original draft: Isabelle Derré.
Writing – review & editing: María Eugenia Cortina, Rachel J. Ende, R. Clayton Bishop.

References
1. Schachter J. Infection and disease epidemiology. In Chlamydia: Intracellular biology, pathogenesis, and immunity (ed. Stephens RS), pp.139–170. American Society for Microbiology, Washington, DC. 1999.
2. Kuo CC, Jackson LA, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev. 1995; 8(4):451–61. PMID: 8665464; PubMed Central PMCID: PMCPMC172870.
3. Everett KD, Bush RM, Andersen AA. Emended description of the order Chlamydiales fam. nov. and Simkaniaceae fam. nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, including a new genus and five new species, and standards for the identification of organisms. Int J Syst Bacteriol. 1999; 49 Pt 2:415–40. https://doi.org/10.1099/00207713-49-2-415 PMID: 10319462.
4. Barron AL, White HJ, Rank RG, Soloff BL, Moses EB. A new animal model for the study of Chlamydia trachomatis genital infections: infection of mice with the agent of mouse pneumonitis. J Infect Dis. 1981; 143(1):63–6. https://doi.org/10.1093/infdis/143.1.63 PMID: 7271717.
5. Moulder JW. Interaction of chlamydiae and host cells in vitro. Microbiol Rev. 1991; 55(1):143–90. PMID: 2030670; PubMed Central PMCID: PMCPMC372804.
6. Abdelrahman YM, Belland RJ. The chlamydial developmental cycle. FEMS Microbiol Rev. 2005; 29 (5):949–59. https://doi.org/10.1016/j.femsre.2005.03.002 PMID: 16043254.
7. Lee JK, Enciso GA, Boassa D, Chander CN, Lou TH, Pairawan SS, et al. Replication-dependent size reduction precedes differentiation in Chlamydia trachomatis. Nat Commun. 2018; 9(1):45. https://doi.org/10.1038/s41467-017-02432-0 PMID: 29298975; PubMed Central PMCID: PMCPMC5752669.
8. Hybiske K, Stephens RS. Mechanisms of host cell exit by the intracellular bacterium Chlamydia. Proc Natl Acad Sci U S A. 2007; 104(27):11430–5. https://doi.org/10.1073/pnas.0703218104 PMID: 17592133; PubMed Central PMCID: PMCPMC2040915.
9. Mueller KE, Plano GV, Fields KA. New frontiers in type III secretion biology: the Chlamydia perspective. Infection and immunity. 2014; 82(1):2–9. https://doi.org/10.1128/IAI.00917-13 PMID: 24126521; PubMed Central PMCID: PMC3911841.
10. Dehoux P, Flores R, Dauga C, Zhong G, Subtil A. Multi-genome identification and characterization of chlamydiae-specific type III secretion substrates: the Inc proteins. BMC Genomics. 2011; 12:109. https://doi.org/10.1186/1471-2164-12-109 PMID: 21324157; PubMed Central PMCID: PMC3048545.
11. Lutter EI, Martens C, Hackstadt T. Evolution and conservation of predicted inclusion membrane proteins in chlamydiae. Comp Funct Genomics. 2012; 2012:362104. https://doi.org/10.1155/2012/362104 PMID: 22454599; PubMed Central PMCID: PMCPMC3290821.
12. Moore ER, Ouellette SP. Reconceptualizing the chlamydial inclusion as a pathogen-specific parasitic organelle: an expanded role for Inc proteins. Front Cell Infect Microbiol. 2014; 4:157. https://doi.org/10.3389/fcimb.2014.00157 PMID: 25401095; PubMed Central PMCID: PMCPMC4215707.
13. Bannantine JP, Griffiths RS, Viratyosin W, Brown WJ, Rockey DD. A secondary structure motif predictive of protein localization to the chlamydial inclusion membrane. Cell Microbiol. 2000; 2(1):35–47. PMID: 11207561.
14. Wang Y, Kahane S, Cutcliffe LT, Skilton RJ, Lambden PR, Clarke IN. Development of a transformation system for Chlamydia trachomatis: restoration of glycogen biosynthesis by acquisition of a plasmid shuttle vector. PLoS pathogens. 2011; 7(9):e1002258. https://doi.org/10.1371/journal.ppat.1002258 PMID: 21966270; PubMed Central PMCID: PMC3178582.
15. Agaisse H, Derré I. A C. trachomatis cloning vector and the generation of C. trachomatis strains expressing fluorescent proteins under the control of a C. trachomatis promoter. PLoS One. 2013; 8(2):e57090. https://doi.org/10.1371/journal.pone.0057090 PMID: 23441233; PubMed Central PMCID: PMCPMC3575495.
16. Wickstrum J, Sammons LR, Restivo KN, Hefty PS. Conditional gene expression in *Chlamydia trachomatis* using the tet system. PLoS One. 2013; 8(10):e76743. https://doi.org/10.1371/journal.pone.0076743 PMID: 24116144; PubMed Central PMCID: PMCPMC3792055.

17. Agaïsse H, Derré I. Expression of the effector protein IncI in *Chlamydia trachomatis* mediates recruitment of the lipid transfer protein CERT and the endoplasmic reticulum-resident protein VAPB to the inclusion membrane. Infection and immunity. 2014; 82(5):2037–47. https://doi.org/10.1128/IAI.01530-14 PMID: 24595143; PubMed Central PMCID: PMC3993449.

18. Bauler LD, Hackstadt T. Expression and targeting of secreted proteins from *Chlamydia trachomatis*. J Bacteriol. 2014; 196(7):1325–34. https://doi.org/10.1128/JB.01290-13 PMID: 24443531; PubMed Central PMCID: PMCPMC3993338.

19. Mueller KE, Fields KA. Application of beta-lactamase reporter fusions as an indicator of effector protein secretion during infections with the obligate intracellular pathogen *Chlamydia trachomatis*. PLoS One. 2015; 10(8):e0135295. https://doi.org/10.1371/journal.pone.0135295 PMID: 26258949; PubMed Central PMCID: PMCPMC4530969.

20. Weber MM, Lam JL, Dooley CA, Noriea NF, Hansen BT, Hoyt FH, et al. Absence of Specific *Chlamydia trachomatis* Inclusion Membrane Proteins Triggers Premature Inclusion Membrane Lysis and Host Cell Death. Cell Rep. 2017; 19(7):1406–17. https://doi.org/10.1016/j.celrep.2017.04.055 PMID: 28514660; PubMed Central PMCID: PMCPMC5499683.

21. Xu S, Battaglia L, Bao X, Fan H. Chloramphenicol acetyltransferase as a selection marker for *Chlamydia trachomatis* virulence mutants. Antimicrob Agents Chemother. 2010; 54(4):1208–15. https://doi.org/10.1128/AAC.01484-09 PMID: 20183578; PubMed Central PMCID: PMCPMC2923664.

22. Mueller KE, Wolf K, Fields KA. Gene Deletion by Fluorescence-Reported Allelic Exchange Mutagenesis in *Chlamydia trachomatis*. MBio. 2016; 7(1):e01817–15. https://doi.org/10.1128/mBio.01817-15 PMID: 26778928; PubMed Central PMCID: PMCPMC4729004.

23. Keb G, Hayman R, Fields KA. Floxed-Cassette Allelic Exchange Mutagenesis Enables Markerless Gene Deletion in *Chlamydia trachomatis* and Can Reverse Cassette-Induced Polar Effects. J Bacteriol. 2018; 200(24). https://doi.org/10.1128/JB.00479-16 PMID: 30224436; PubMed Central PMCID: PMCPMC6256029.

24. Lutter EI, Barger AC, Nair V, Hackstadt T. *Chlamydia trachomatis* inclusion membrane protein CT228 recruits elements of the myosin phosphatase pathway to regulate release mechanisms. Cell Rep. 2013; 3(6):1921–31. https://doi.org/10.1016/j.celrep.2013.04.027 PMID: 23727243; PubMed Central PMCID: PMCPMC3700685.

25. Mital J, Lutter EI, Barger AC, Dooley CA, Hackstadt T. *Chlamydia trachomatis* inclusion membrane protein CT850 interacts with the dynein light chain DYNLT1 (Tctex1). Biochem Biophys Res Commun. 2015; 462(2):165–70. https://doi.org/10.1016/j.bbrc.2015.04.116 PMID: 25944661; PubMed Central PMCID: PMCPMC4449824.

26. Aeberhard L, Banhart S, Fischer M, Jehmlich N, Rose L, Koch S, et al. The Proteome of the Isolated *Chlamydia trachomatis* Containing Vacuole Reveals a Complex Trafficking Platform Enriched for Retromer Components. PLoS pathog. 2015; 11(6):e1004883. https://doi.org/10.1371/journal.ppat.1004883 PMID: 26042774; PubMed Central PMCID: PMCPMC45456400.

27. Mirrashidi KM, Elwell CA, Verschueren E, Johnson JR, Frando A, Von Dollen J, et al. Global Mapping of the Inc-Human Interactome Reveals that Retromer Restricts *Chlamydia* Infection. Cell Host Microbe. 2015; 18(1):109–21. https://doi.org/10.1016/j.chom.2015.06.004 PMID: 26118995; PubMed Central PMCID: PMCPMC4540348.

28. Mital J, Miller NJ, Fischer ER, Hackstadt T. Specific chlamydial inclusion membrane proteins associate with active Src family kinases in microdomains that interact with the host microtubule network. Cell Microbiol. 2010; 12(9):1235–49. https://doi.org/10.1111/j.1462-5882.2010.01465.x PMID: 20331642; PubMed Central PMCID: PMCPMC2923664.

29. Stanhope R, Flora E, Bayne C, Derré I. IncV, a FFAT motif-containing *Chlamydia* protein, tethers the endoplasmic reticulum to the pathogen-containing vacuole. Proc Natl Acad Sci U S A. 2017; 114(45):12039–44. https://doi.org/10.1073/pnas.1709060114 PMID: 29078338; PubMed Central PMCID: PMCPMC5692559.

30. Nguyen PH, Lutter EI, Hackstadt T. *Chlamydia trachomatis* inclusion membrane protein MrcA interacts with the inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) to regulate extrusion formation. PLoS pathogens. 2018; 14(3):e1006911. https://doi.org/10.1371/journal.ppat.1006911 PMID: 29543918; PubMed Central PMCID: PMCPMC5854415.

31. Kokes M, Dunn JD, Granek JA, Nguyen BD, Barker JR, Valdivia RH, et al. Integrating chemical mutagenesis and whole-genome sequencing as a platform for forward and reverse genetic analysis of *Chlamydia*. Cell Host Microbe. 2015; 17(5):716–25. https://doi.org/10.1016/j.chom.2015.03.014 PMID: 25920978; PubMed Central PMCID: PMCPMC4418230.
32. Wesolowski J, Weber MM, Nawrotek A, Dooley CA, Calderon M, St Croix CM, et al. Chlamydia Hijacks ARF GTPases To Coordinate Microtubule Posttranslational Modifications and Golgi Complex Positioning. MBio. 2017; 8(3). https://doi.org/10.1128/mBio.02280-16 PMID: 28465429; PubMed Central PMCID: PMCPMC4544008.

33. Sixt BS, Bastidas RJ, Finethy R, Baxter RM, Carpenter VK, Kroemer G, et al. The Chlamydia trachomatis Inclusion Membrane Protein CpoS Counteracts STING-Mediated Cellular Surveillance and Suicide Programs. Cell Host Microbe. 2017; 21(1):113–21. https://doi.org/10.1016/j.chom.2016.12.002 PMID: 28041929; PubMed Central PMCID: PMCPMC5235904.

34. Song L, Carlson JH, Zhou B, Virtanenva K, Whitmire WM, Sturdevant GL, et al. Plasmid-mediated transformation tropism of chlamydial biovars. Pathog Dis. 2014; 70(2):189–93. https://doi.org/10.1111/2049-632X.12104 PMID: 24214488; PubMed Central PMCID: PMCPMC3959247.

35. Wang Y, Cutcliffe LT, Skilton RJ, Ramsey KH, Thomson NR, Clarke IN. The genetic basis of plasmid transformation tropism between Chlamydia trachomatis and Chlamydia muridarum. Pathog Dis. 2014; 72(1):19–23. https://doi.org/10.1111/2049-632X.12175 PMID: 24708015; PubMed Central PMCID: PMCPMC4314687.

36. Shima K, Wanker M, Skilton RJ, Cutcliffe LT, Schnee C, Kohl TA, et al. The Genetic Transformation of Chlamydia pneumoniae. mSphere. 2018; 3(5). https://doi.org/10.1128/mSphere.00142-18 PMID: 30306318; PubMed Central PMCID: PMCPMC6180227.

37. Campbell J, Huang Y, Liu Y, Schenkren K, Arulananandam B, Zhong G. Bioluminescence imaging of Chlamydia muridarum ascending infection in mice. PLoS One. 2014; 9(7):e101634. https://doi.org/10.1371/journal.pone.0101634; PubMed Central PMCID: PMCPMC4077829.

38. Liu Y, Chen C, Gong S, Hou S, Qi M, Liu Q, et al. Transformation of Chlamydia trachomatis reveals a role for Pgp5 in suppression of plasmid-dependent gene expression. J Bacteriol. 2014; 196(5):989–98. https://doi.org/10.1128/JB.01161-13 PMID: 24363544; PubMed Central PMCID: PMCPMC3957687.

39. Skilton RJ, Wang Y, O’Neill C, Filardo S, Marsh P, Benard A, et al. The Chlamydia muridarum plasmid revisited: new insights into growth kinetics. Wellcome Open Res. 2018; 3:25. https://doi.org/10.12688/wellcomeopenres.13905.1 PMID: 29657985; PubMed Central PMCID: PMCPMC581946.

40. Shaw EI, Dooley CA, Fischer ER, Scidmore MA, Fields KA, Hackstadt T. Three temporal classes of gene expression during the Chlamydia trachomatis developmental cycle. Mol Microbiol. 2000; 37(4):913–25. PMID: 10972811.

41. Belland RJ, Zhong G, Crane DD, Hogan D, Sturdevant D, Sharma J, et al. Genomic transcriptional profiling of the developmental cycle of Chlamydia trachomatis. Proc Natl Acad Sci U S A. 2003; 100(14):8478–83. https://doi.org/10.1073/pnas.1331135100 PMID: 12815105; PubMed Central PMCID: PMCPMC166254.

42. Hatch TP, Miceli M, Sublett JE. Synthesis of disulfide-bonded outer membrane proteins during the developmental cycle of Chlamydia psittaci and Chlamydia trachomatis. J Bacteriol. 1986; 165(2):379–85. https://doi.org/10.1128/jb.165.2.379-385.1986 PMID: 3944054; PubMed Central PMCID: PMCPMC214428.

43. Clarke IN, Ward ME, Lambden PR. Molecular cloning and sequence analysis of a developmentally regulated cysteine-rich outer membrane protein from Chlamydia trachomatis. Gene. 1988; 71(2):307–14. PMID: 3066701.

44. Sardinia LM, Segal E, Ganem D. Developmental regulation of the cysteine-rich outer-membrane proteins of murine Chlamydia trachomatis. J Gen Microbiol. 1988; 134(4):997–1004. https://doi.org/10.1099/00221287-134-4.997 PMID: 3183625.

45. Fadel S, Eley A. Chlamydia trachomatis OmcB protein is a surface-exposed glycosaminoglycan-dependent adhesin. J Med Microbiol. 2007; 56(Pt 1):15–22. https://doi.org/10.1099/jmm.0.46801-0 PMID: 17172511.

46. Rosario CJ, Tan M. The early gene product E08 is a transcriptional repressor that selectively regulates promoters of Chlamydia late genes. Mol Microbiol. 2012; 84(6):907–107. https://doi.org/10.1111/j.1365-2958.2012.08077.x PMID: 22624851; PubMed Central PMCID: PMCPMC3544401.

47. Wilson DP, Timms P, McElwain DL, Bavoil PM. Type III secretion, contact-dependent model for the intracellular development of chlamydia. Bull Math Biol. 2006; 68(1):161–78. https://doi.org/10.1007/s11538-005-9024-1 PMID: 16794925.

48. Derré I, Pypaert M, Dautry-Varsat A, Agaisse H. RNAi screen in Drosophila cells reveals the involvement of the Tom complex in Chlamydia infection. PLoS pathogens. 2007; 3(10):1446–58. https://doi. org/10.1371/journal.ppat.0030155 PMID: 17967059; PubMed Central PMCID: PMCPMC2042019.

49. Lowden NM, Yeruva L, Johnson CM, Bowlin AK, Fisher DJ. Use of aminoglycoside 3’ adenylytransferase as a selection marker for Chlamydia trachomatis intron-mutagenesis and in vivo intron stability. BMC Res Notes. 2015; 8:570. https://doi.org/10.1186/s13104-015-1542-9 PMID: 26471806; PubMed Central PMCID: PMCPMC4606545.

PLOS ONE | https://doi.org/10.1371/journal.pone.0217753 June 6, 2019 22 / 23
50. Murphy E. Nucleotide sequence of a spectinomycin adenyltransferase AAD(9) determinant from *Staphylococcus aureus* and its relationship to AAD(3') (9). Mol Gen Genet. 1985; 200(1):33–9. PMID: 2993813.

51. Han Y, Derré I. A Co-infection Model System and the Use of Chimeric Proteins to Study Chlamydia Inclusion Proteins Interaction. Front Cell Infect Microbiol. 2017; 7:79. https://doi.org/10.3389/fcimb.2017.00079 PMID: 28352612; PubMed Central PMCID: PMCPMC5348484.

52. Key CE, Fisher DJ. Use of Group II Intron Technology for Targeted Mutagenesis in *Chlamydia trachomatis*. Methods Mol Biol. 2017; 1498:163–77. https://doi.org/10.1007/978-1-4939-6472-7_11 PMID: 27709575.

53. Lyons JM, Ito Jr., Pena AS, Morre SA. Differences in growth characteristics and elementary body associated cytopathicity between *Chlamydia trachomatis* ocular/gential serovars D and H and *Chlamydia muridarum*. J Clin Pathol. 2005; 58(4):397–401. https://doi.org/10.1136/jcp.2004.021543 PMID: 15790704; PubMed Central PMCID: PMCPMC1770636.

54. Hackstadt T, Rockey DD, Heinzen RA, Scidmore MA. *Chlamydia trachomatis* interrupts an exocytic pathway to acquire endogenously synthesized sphingomyelin in transit from the Golgi apparatus to the plasma membrane. EMBO J. 1996; 15(5):964–77. PMID: 8605892; PubMed Central PMCID: PMCPMC449991.